FreeGuest Editorial What cancer immunologists are doing about COVID-19 April 03, 2020Vol.46 No.14By Rachel Humphrey
COVID-19 & CancerFreeGuest Editorial Friending viral foes: The Zika story and (perhaps) lessons for COVID-19 April 03, 2020Vol.46 No.14By Scott M. Lippman
COVID-19 & CancerFreeGuest Editorial The COVID-19 pandemic gives us the urgency—and one more chance—to address health disparities March 20, 2020Vol.46 No.12By Robert A. Winn
COVID-19 & CancerFreeGuest Editorial ASCO’s Response to COVID-19 March 18, 2020Vol.46 No.12By Richard L. Schilsky
COVID-19 & CancerFreeGuest Editorial COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk March 13, 2020Vol.46 No.11By Karen E. Knudsen and Roy A. Jensen
FreeGuest Editorial Lung-MAP: A five-year recap on the first master protocol trial in cancer research February 21, 2020Vol.46 No.08By Roy S. Herbst, Lyudmila Bazhenova, Joel Neal and Saiama N. Waqar
FreeGuest Editorial Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall January 08, 2020Vol.46 No.02By Otis W. Brawley
FreeGuest Editorial FDA e-cigarette flavoring ban leaves a bad taste“Trump eroding role of science in government” January 03, 2020Vol.46 No.01By Alan Blum
FreeGuest Editorial Museum malignancy:What the Sacklers and Philip Morris have in common October 18, 2019Vol.45 No.39By Alan Blum
Guest Editorial Herceptin: What it took to make it happen September 20, 2019Vol.45 No.35By Robert Bazell
